Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway
Open Access
- 8 February 2024
- journal article
- research article
- Published by Springer Nature in npj Digital Medicine
- Vol. 7 (1) , 1-8
Abstract
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between the 510(k) process —the historically dominant path to market for most medical devices— and the De Novo pathway, a more recent alternative that targets more novel devices, including those involving new technologies, diagnostics, hardware, and software. The De Novo pathway holds significant potential for innovators seeking to define new categories of medical devices, as it represents a less burdensome approach than would have otherwise been needed historically. Moreover, it supports the FDA in its effort to modernize the long-established 510(k) pathway by promoting the availability of up-to-date device “predicates” upon which subsequent device applications can be based, reflecting positive spillovers that are likely to encourage manufacturers to adopt current state-of-the-art technologies and modern standards of safety and effectiveness. We analyze the of characteristics all the De Novo classification requests to date, including the submission type, trends, FDA review times, and device types. After characterizing how the De Novo process has been used over time, we discuss its unique challenges and opportunities with respect to medical device software and AI-enabled devices, including considerations for intellectual property, innovation, and competition economics.Keywords
Funding Information
- Novo Nordisk Fonden (NNF23SA0087056))
This publication has 10 references indexed in Scilit:
- Association Between Regulatory Submission Characteristics and Recalls of Medical Devices Receiving 510(k) ClearanceJAMA, 2023
- FDA Regulation and Approval of Medical Devices: 1976-2020JAMA, 2021
- Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019JAMA Internal Medicine, 2020
- The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicineRegulation & Governance, 2020
- The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online databasenpj Digital Medicine, 2020
- TranscriptomicsNature Biotechnology, 2020
- FDA Approval and Regulation of Pharmaceuticals, 1983-2018JAMA, 2020
- Regulatory responses to medical machine learningJournal of Law and the Biosciences, 2020
- Innovation under regulatory uncertainty: Evidence from medical technologyJournal of Public Economics, 2017
- Modernizing Device RegulationNew England Journal of Medicine, 2010